{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:27:48Z","timestamp":1793921268974,"version":"4.8.0"},"reference-count":199,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82272332"],"award-info":[{"award-number":["82272332"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82203652"],"award-info":[{"award-number":["82203652"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06643-8","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T05:00:12Z","timestamp":1748926812000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Unraveling the role of M2 TAMs in ovarian cancer dynamics: a systematic review"],"prefix":"10.1186","volume":"23","author":[{"given":"Yaping","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caixia","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiabing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaili","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengnan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"6643_CR1","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1007\/s12013-024-01385-8","volume":"82","author":"B Chen","year":"2024","unstructured":"Chen B, Liu J. Advances in ovarian tumor stem cells and therapy. Cell Biochem Biophys. 2024;82:1871\u201392. https:\/\/doi.org\/10.1007\/s12013-024-01385-8","journal-title":"Cell Biochem Biophys"},{"key":"6643_CR2","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.2174\/1389450117666160502150237","volume":"18","author":"W Zhang","year":"2017","unstructured":"Zhang W, Shen Z, Luo H, Hu X, Zheng L, Zhu X. The benefits and side effects of bevacizumab for the treatment of recurrent ovarian Cancer. Curr Drug Targets. 2017;18:1125\u201331. https:\/\/doi.org\/10.2174\/1389450117666160502150237","journal-title":"Curr Drug Targets"},{"key":"6643_CR3","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.20517\/cdr.2019.76","volume":"2","author":"MAA Padilla","year":"2019","unstructured":"Padilla MAA, Binju M, Wan G, Rahmanto YS, Kaur P, Yu Y. Relationship between ovarian cancer stem cells, epithelial mesenchymal transition and tumour recurrence. Cancer Drug Resist. 2019;2:1127\u201335. https:\/\/doi.org\/10.20517\/cdr.2019.76","journal-title":"Cancer Drug Resist"},{"key":"6643_CR4","doi-asserted-by":"publisher","unstructured":"Mehra P, Aditi S, Prasad KM, Bariar NK. Histomorphological Analysis of Ovarian Neoplasms According to the 2020 WHO Classification of Ovarian Tumors: A Distribution Pattern in a Tertiary Care Center. Cureus. 2023;15:e38273. https:\/\/doi.org\/10.7759\/cureus.38273","DOI":"10.7759\/cureus.38273"},{"key":"6643_CR5","doi-asserted-by":"publisher","unstructured":"Moufarrij S, Dandapani M, Arthofer E, Gomez S, Srivastava A, Lopez-Acevedo M, Villagra A, Chiappinelli KB. Epigenetic therapy for ovarian cancer: promise and progress. Clin Epigenetics. 2019;11. https:\/\/doi.org\/10.1186\/s13148-018-0602-0","DOI":"10.1186\/s13148-018-0602-0"},{"key":"6643_CR6","doi-asserted-by":"publisher","first-page":"115151","DOI":"10.1016\/j.biopha.2023.115151","volume":"165","author":"OD Ogundipe","year":"2023","unstructured":"Ogundipe OD, Olajubutu O, Adesina SK. Targeted drug conjugate systems for ovarian cancer chemotherapy. Biomed Pharmacother. 2023;165:115151. https:\/\/doi.org\/10.1016\/j.biopha.2023.115151","journal-title":"Biomed Pharmacother"},{"key":"6643_CR7","doi-asserted-by":"publisher","unstructured":"Haines NA, Fowler MG, Zeh BG, Kriete CB, Bai Q, Wakefield MR, Fang Y. Unlocking the \u2018ova\u2019-coming power: immunotherapy\u2019s role in shaping the future of ovarian cancer treatment. Med Oncol. 2024;41. https:\/\/doi.org\/10.1007\/s12032-023-02281-6","DOI":"10.1007\/s12032-023-02281-6"},{"key":"6643_CR8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.soncn.2019.02.001","volume":"35","author":"C Stewart","year":"2019","unstructured":"Stewart C, Ralyea C, Lockwood S. Ovarian cancer: an integrated review. Semin Oncol Nurs. 2019;35:151\u20136. https:\/\/doi.org\/10.1016\/j.soncn.2019.02.001","journal-title":"Semin Oncol Nurs"},{"key":"6643_CR9","doi-asserted-by":"publisher","first-page":"556","DOI":"10.34172\/apb.2020.066","volume":"10","author":"S Malekghasemi","year":"2020","unstructured":"Malekghasemi S, Majidi J, Baghbanzadeh A, Abdolalizadeh J, Baradaran B, Aghebati-Maleki L. Tumor-Associated macrophages: protumoral macrophages in inflammatory tumor microenvironment. Adv Pharm Bull. 2020;10:556\u201365. https:\/\/doi.org\/10.34172\/apb.2020.066","journal-title":"Adv Pharm Bull"},{"key":"6643_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3779\/j.issn.1009-3419.2024.102.13","volume":"27","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Ren D, Bi H, Yi B, Zhang C, Wang H, Sun J. [Tumor-associated macrophage: emerging targets for modulating the tumor microenvironment]. Zhongguo Fei Ai Za Zhi. 2024;27:231\u201340. https:\/\/doi.org\/10.3779\/j.issn.1009-3419.2024.102.13","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"6643_CR11","doi-asserted-by":"publisher","unstructured":"Boutilier AJ, Elsawa SF. Macrophage polarization States in the tumor microenvironment. Int J Mol Sci. 2021;22. https:\/\/doi.org\/10.3390\/ijms22136995","DOI":"10.3390\/ijms22136995"},{"key":"6643_CR12","doi-asserted-by":"publisher","first-page":"1476565","DOI":"10.3389\/fimmu.2024.1476565","volume":"15","author":"J Cao","year":"2024","unstructured":"Cao J, Liu C. Mechanistic studies of tumor-associated macrophage immunotherapy. Front Immunol. 2024;15:1476565. https:\/\/doi.org\/10.3389\/fimmu.2024.1476565","journal-title":"Front Immunol"},{"key":"6643_CR13","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.7150\/thno.92672","volume":"14","author":"SMP Vadevoo","year":"2024","unstructured":"Vadevoo SMP, Kang Y, Gunassekaran GR, Lee SM, Park MS, Jo DG, Kim SK, Lee H, Kim WJ, Lee B. IL4 receptor targeting enables nab-paclitaxel to enhance reprogramming of M2-type macrophages into M1-like phenotype via ROS-HMGB1-TLR4 axis and Inhibition of tumor growth and metastasis. Theranostics. 2024;14:2605\u201321. https:\/\/doi.org\/10.7150\/thno.92672","journal-title":"Theranostics"},{"key":"6643_CR14","doi-asserted-by":"publisher","unstructured":"Schweer D, McAtee A, Neupane K, Richards C, Ueland F, Kolesar J. Tumor-Associated macrophages and ovarian cancer: implications for therapy. Cancers (Basel). 2022;14. https:\/\/doi.org\/10.3390\/cancers14092220","DOI":"10.3390\/cancers14092220"},{"key":"6643_CR15","doi-asserted-by":"publisher","unstructured":"Scott AL, Jazwinska DE, Kulawiec DG, Zervantonakis IK. Paracrine ovarian Cancer Cell-Derived CSF1 signaling regulates macrophage migration dynamics in a 3D microfluidic model that recapitulates in vivo infiltration patterns in Patient\u2010Derived xenografts. Adv Healthc Mater. 2024;13. https:\/\/doi.org\/10.1002\/adhm.202401719","DOI":"10.1002\/adhm.202401719"},{"key":"6643_CR16","doi-asserted-by":"publisher","first-page":"C721","DOI":"10.1152\/ajpcell.00461.2022","volume":"325","author":"DE Jazwinska","year":"2023","unstructured":"Jazwinska DE, Kulawiec DG, Zervantonakis IK. Cancer-mesothelial and cancer-macrophage interactions in the ovarian cancer microenvironment. Am J Physiology-Cell Physiol. 2023;325:C721\u201330. https:\/\/doi.org\/10.1152\/ajpcell.00461.2022","journal-title":"Am J Physiology-Cell Physiol"},{"key":"6643_CR17","doi-asserted-by":"publisher","unstructured":"Su P, Li O, Ke K, Jiang Z, Wu J, Wang Y, Mou Y, Jin W. Targeting tumor\u2013associated macrophages: critical players in tumor progression and therapeutic strategies (Review). Int J Oncol. 2024;64. https:\/\/doi.org\/10.3892\/ijo.2024.5648","DOI":"10.3892\/ijo.2024.5648"},{"key":"6643_CR18","doi-asserted-by":"publisher","unstructured":"Pan Y, Yu Y, Wang X, Zhang T. Tumor-Associated macrophages in tumor immunity. Front Immunol. 2020;11. https:\/\/doi.org\/10.3389\/fimmu.2020.583084","DOI":"10.3389\/fimmu.2020.583084"},{"key":"6643_CR19","doi-asserted-by":"publisher","unstructured":"Liu Y, Wang R. Immunotherapy targeting Tumor-Associated macrophages. Front Med. 2020;7. https:\/\/doi.org\/10.3389\/fmed.2020.583708","DOI":"10.3389\/fmed.2020.583708"},{"key":"6643_CR20","doi-asserted-by":"publisher","unstructured":"Li J, DeNicola GM, Ruffell B. Metabolism in tumor-associated macrophages. In One, No one, One Hundred Thousand - The Multifaceted Role of Macrophages in Health and Disease - Part A. 2022:65\u2013100. https:\/\/doi.org\/10.1016\/bs.ircmb.2022.01.004","DOI":"10.1016\/bs.ircmb.2022.01.004"},{"key":"6643_CR21","doi-asserted-by":"publisher","first-page":"e12874","DOI":"10.1590\/1414-431X2024e12874","volume":"57","author":"Y Liu","year":"2024","unstructured":"Liu Y, Yi T, Meng S, Zhao X, Chen X, Zhang Y. Trichostatin A-modified vaccine provides superior protection against ovarian cancer formation and development. Braz J Med Biol Res. 2024;57:e12874. https:\/\/doi.org\/10.1590\/1414-431X2024e12874","journal-title":"Braz J Med Biol Res"},{"key":"6643_CR22","doi-asserted-by":"publisher","unstructured":"Greppi M, Tabellini G, Patrizi O, Candiani S, Decensi A, Parolini S, Sivori S, Pesce S, Paleari L, Marcenaro E. Strengthening the antitumor NK cell function for the treatment of ovarian Cancer. Int J Mol Sci. 2019;20. https:\/\/doi.org\/10.3390\/ijms20040890","DOI":"10.3390\/ijms20040890"},{"key":"6643_CR23","doi-asserted-by":"publisher","unstructured":"Baci D, Bosi A, Gallazzi M, Rizzi M, Noonan DM, Poggi A, Bruno A, Mortara L. The ovarian Cancer tumor immune microenvironment (TIME) as target for therapy: A focus on innate immunity cells as therapeutic effectors. Int J Mol Sci. 2020;21. https:\/\/doi.org\/10.3390\/ijms21093125","DOI":"10.3390\/ijms21093125"},{"key":"6643_CR24","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.3389\/fimmu.2019.01273","volume":"10","author":"T Baert","year":"2019","unstructured":"Baert T, Vankerckhoven A, Riva M, Van Hoylandt A, Thirion G, Holger G, Mathivet T, Vergote I, Coosemans A. Myeloid derived suppressor cells: key drivers of immunosuppression in ovarian Cancer. Front Immunol. 2019;10:1273. https:\/\/doi.org\/10.3389\/fimmu.2019.01273","journal-title":"Front Immunol"},{"key":"6643_CR25","doi-asserted-by":"publisher","unstructured":"Gupta V, Yull F, Khabele D. Bipolar Tumor-Associated macrophages in ovarian Cancer as targets for therapy. Cancers (Basel). 2018;10. https:\/\/doi.org\/10.3390\/cancers10100366","DOI":"10.3390\/cancers10100366"},{"key":"6643_CR26","doi-asserted-by":"publisher","first-page":"107627","DOI":"10.1016\/j.intimp.2021.107627","volume":"96","author":"HR Lan","year":"2021","unstructured":"Lan HR, Du WL, Liu Y, Mao CS, Jin KT, Yang X. Role of immune regulatory cells in breast cancer: foe or friend? Int Immunopharmacol. 2021;96:107627. https:\/\/doi.org\/10.1016\/j.intimp.2021.107627","journal-title":"Int Immunopharmacol"},{"key":"6643_CR27","doi-asserted-by":"publisher","first-page":"104119","DOI":"10.1016\/j.cellimm.2020.104119","volume":"353","author":"LQ Fu","year":"2020","unstructured":"Fu LQ, Du WL, Cai MH, Yao JY, Zhao YY, Mou XZ. The roles of tumor-associated macrophages in tumor angiogenesis and metastasis. Cell Immunol. 2020;353:104119. https:\/\/doi.org\/10.1016\/j.cellimm.2020.104119","journal-title":"Cell Immunol"},{"key":"6643_CR28","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s00432-024-05777-4","volume":"150","author":"R Huang","year":"2024","unstructured":"Huang R, Kang T, Chen S. The role of tumor-associated macrophages in tumor immune evasion. J Cancer Res Clin Oncol. 2024;150:238. https:\/\/doi.org\/10.1007\/s00432-024-05777-4","journal-title":"J Cancer Res Clin Oncol"},{"key":"6643_CR29","doi-asserted-by":"publisher","first-page":"7492","DOI":"10.1016\/j.cell.2024.10.006","volume":"187","author":"G Mollaoglu","year":"2024","unstructured":"Mollaoglu G, Tepper A, Falcomata C, Potak HT, Pia L, Amabile A, Mateus-Tique J, Rabinovich N, Park MD, LaMarche NM, et al. Ovarian cancer-derived IL-4 promotes immunotherapy resistance. Cell. 2024;187:7492\u2013e75107422. https:\/\/doi.org\/10.1016\/j.cell.2024.10.006","journal-title":"Cell"},{"key":"6643_CR30","doi-asserted-by":"publisher","first-page":"154739","DOI":"10.1016\/j.prp.2023.154739","volume":"249","author":"J Song","year":"2023","unstructured":"Song J, Xiao T, Li M, Jia Q. Tumor-associated macrophages: potential therapeutic targets and diagnostic markers in cancer. Pathol Res Pract. 2023;249:154739. https:\/\/doi.org\/10.1016\/j.prp.2023.154739","journal-title":"Pathol Res Pract"},{"key":"6643_CR31","doi-asserted-by":"publisher","unstructured":"Dunn ZS, Li YR, Yu Y, Lee D, Gibbons A, Kim JJ, Zhou TY, Li M, Nguyen M, Cen X, et al. Minimally invasive preclinical monitoring of the peritoneal cavity tumor microenvironment. Cancers (Basel). 2022;14. https:\/\/doi.org\/10.3390\/cancers14071775","DOI":"10.3390\/cancers14071775"},{"key":"6643_CR32","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1007\/s11010-022-04461-w","volume":"477","author":"D Yang","year":"2022","unstructured":"Yang D, Yang L, Cai J, Li H, Xing Z, Hou Y. Phosphoinositide 3-kinase\/Akt and its related signaling pathways in the regulation of tumor-associated macrophages polarization. Mol Cell Biochem. 2022;477:2469\u201380. https:\/\/doi.org\/10.1007\/s11010-022-04461-w","journal-title":"Mol Cell Biochem"},{"key":"6643_CR33","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.humimm.2022.02.007","volume":"83","author":"KK Goswami","year":"2022","unstructured":"Goswami KK, Banerjee S, Bose A, Baral R. Lactic acid in alternative polarization and function of macrophages in tumor microenvironment. Hum Immunol. 2022;83:409\u201317. https:\/\/doi.org\/10.1016\/j.humimm.2022.02.007","journal-title":"Hum Immunol"},{"key":"6643_CR34","doi-asserted-by":"publisher","first-page":"1452078","DOI":"10.3389\/fimmu.2024.1452078","volume":"15","author":"W Li","year":"2024","unstructured":"Li W, Yuan Q, Li M, He X, Shen C, Luo Y, Tai Y, Li Y, Deng Z, Luo Y. Research advances on signaling pathways regulating the polarization of tumor-associated macrophages in lung cancer microenvironment. Front Immunol. 2024;15:1452078. https:\/\/doi.org\/10.3389\/fimmu.2024.1452078","journal-title":"Front Immunol"},{"key":"6643_CR35","doi-asserted-by":"publisher","unstructured":"Laviron M, Boissonnas A. Ontogeny of Tumor-Associated macrophages. Front Immunol. 2019;10. https:\/\/doi.org\/10.3389\/fimmu.2019.01799","DOI":"10.3389\/fimmu.2019.01799"},{"key":"6643_CR36","doi-asserted-by":"publisher","first-page":"106471","DOI":"10.1016\/j.intimp.2020.106471","volume":"84","author":"Y Yousefzadeh","year":"2020","unstructured":"Yousefzadeh Y, Hallaj S, Baghi Moornani M, Asghary A, Azizi G, Hojjat-Farsangi M, Ghalamfarsa G, Jadidi-Niaragh F. Tumor associated macrophages in the molecular pathogenesis of ovarian cancer. Int Immunopharmacol. 2020;84:106471. https:\/\/doi.org\/10.1016\/j.intimp.2020.106471","journal-title":"Int Immunopharmacol"},{"key":"6643_CR37","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3389\/fonc.2019.00421","volume":"9","author":"H Cheng","year":"2019","unstructured":"Cheng H, Wang Z, Fu L, Xu T. Macrophage polarization in the development and progression of ovarian cancers: an overview. Front Oncol. 2019;9:421. https:\/\/doi.org\/10.3389\/fonc.2019.00421","journal-title":"Front Oncol"},{"key":"6643_CR38","doi-asserted-by":"publisher","unstructured":"Etzerodt A, Moulin M, Doktor TK, Delfini M, Mossadegh-Keller N, Bajenoff M, Sieweke MH, Moestrup SK, Auphan-Anezin N, Lawrence T. Tissue-resident macrophages in omentum promote metastatic spread of ovarian cancer. J Exp Med. 2020;217. https:\/\/doi.org\/10.1084\/jem.20191869","DOI":"10.1084\/jem.20191869"},{"key":"6643_CR39","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nature13989","volume":"518","author":"E Gomez Perdiguero","year":"2015","unstructured":"Gomez Perdiguero E, Klapproth K, Schulz C, Busch K, Azzoni E, Crozet L, Garner H, Trouillet C, de Bruijn MF, Geissmann F, Rodewald HR. Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature. 2015;518:547\u201351. https:\/\/doi.org\/10.1038\/nature13989","journal-title":"Nature"},{"key":"6643_CR40","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ajpath.2013.09.017","volume":"184","author":"SY Ko","year":"2014","unstructured":"Ko SY, Ladanyi A, Lengyel E, Naora H. Expression of the homeobox gene HOXA9 in ovarian cancer induces peritoneal macrophages to acquire an M2 tumor-promoting phenotype. Am J Pathol. 2014;184:271\u201381. https:\/\/doi.org\/10.1016\/j.ajpath.2013.09.017","journal-title":"Am J Pathol"},{"key":"6643_CR41","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1172\/JCI84427","volume":"126","author":"AT Henze","year":"2016","unstructured":"Henze AT, Mazzone M. The impact of hypoxia on tumor-associated macrophages. J Clin Invest. 2016;126:3672\u20139. https:\/\/doi.org\/10.1172\/JCI84427","journal-title":"J Clin Invest"},{"key":"6643_CR42","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1161\/ATVBAHA.117.310333","volume":"38","author":"R Batra","year":"2018","unstructured":"Batra R, Suh MK, Carson JS, Dale MA, Meisinger TM, Fitzgerald M, Opperman PJ, Luo J, Pipinos II, Xiong W, Baxter BT. IL-1beta (Interleukin-1beta) and TNF-alpha (Tumor necrosis Factor-alpha) impact abdominal aortic aneurysm formation by differential effects on macrophage polarization. Arterioscler Thromb Vasc Biol. 2018;38:457\u201363. https:\/\/doi.org\/10.1161\/ATVBAHA.117.310333","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"6643_CR43","doi-asserted-by":"publisher","first-page":"14756","DOI":"10.1074\/jbc.M113.466169","volume":"288","author":"P Baran","year":"2013","unstructured":"Baran P, Nitz R, Grotzinger J, Scheller J, Garbers C. Minimal Interleukin 6 (IL-6) receptor stalk composition for IL-6 receptor shedding and IL-6 classic signaling. J Biol Chem. 2013;288:14756\u201368. https:\/\/doi.org\/10.1074\/jbc.M113.466169","journal-title":"J Biol Chem"},{"key":"6643_CR44","doi-asserted-by":"publisher","unstructured":"Xu M, Mizoguchi I, Morishima N, Chiba Y, Mizuguchi J, Yoshimoto T. Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. Clin Dev Immunol. 2010;2010. https:\/\/doi.org\/10.1155\/2010\/832454","DOI":"10.1155\/2010\/832454"},{"key":"6643_CR45","doi-asserted-by":"publisher","first-page":"104332","DOI":"10.1016\/j.dci.2021.104332","volume":"129","author":"H Qiao","year":"2022","unstructured":"Qiao H, Wang Y, Zhang X, Lu R, Niu J, Nan F, Ke D, Zeng Z, Wang Y, Wang B. Cross-species opsonic activity of zebrafish fish-egg lectin on mouse macrophages. Dev Comp Immunol. 2022;129:104332. https:\/\/doi.org\/10.1016\/j.dci.2021.104332","journal-title":"Dev Comp Immunol"},{"key":"6643_CR46","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00011-004-1279-8","volume":"53","author":"R Pichika","year":"2004","unstructured":"Pichika R, Homandberg GA. Fibronectin fragments elevate nitric oxide (NO) and inducible NO synthetase (iNOS) levels in bovine cartilage and iNOS inhibitors block fibronectin fragment mediated damage and promote repair. Inflamm Res. 2004;53:405\u201312. https:\/\/doi.org\/10.1007\/s00011-004-1279-8","journal-title":"Inflamm Res"},{"key":"6643_CR47","doi-asserted-by":"publisher","first-page":"R80","DOI":"10.1186\/ar3005","volume":"12","author":"Y Yamaguchi","year":"2010","unstructured":"Yamaguchi Y, Takahashi H, Satoh T, Okazaki Y, Mizuki N, Takahashi K, Ikezawa Z, Kuwana M. Natural killer cells control a T-helper 1 response in patients with Behcet\u2019s disease. Arthritis Res Ther. 2010;12:R80. https:\/\/doi.org\/10.1186\/ar3005","journal-title":"Arthritis Res Ther"},{"key":"6643_CR48","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1667\/RR0981.1","volume":"168","author":"HR Park","year":"2007","unstructured":"Park HR, Jung U, Jo SK. Impairment of natural killer (NK) cells is an important factor in a weak Th1-like response in irradiated mice. Radiat Res. 2007;168:446\u201352. https:\/\/doi.org\/10.1667\/RR0981.1","journal-title":"Radiat Res"},{"key":"6643_CR49","doi-asserted-by":"publisher","first-page":"109539","DOI":"10.1016\/j.cellsig.2020.109539","volume":"68","author":"AA El-Arabey","year":"2020","unstructured":"El-Arabey AA, Denizli M, Kanlikilicer P, Bayraktar R, Ivan C, Rashed M, Kabil N, Ozpolat B, Calin GA, Salama SA, et al. GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma. Cell Signal. 2020;68:109539. https:\/\/doi.org\/10.1016\/j.cellsig.2020.109539","journal-title":"Cell Signal"},{"key":"6643_CR50","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.cyto.2013.07.024","volume":"64","author":"R Giannice","year":"2013","unstructured":"Giannice R, Erreni M, Allavena P, Buscaglia M, Tozzi R. Chemokines mRNA expression in relation to the macrophage migration inhibitory factor (MIF) mRNA and vascular endothelial growth factor (VEGF) mRNA expression in the microenvironment of endometrial cancer tissue and normal endometrium: a pilot study. Cytokine. 2013;64:509\u201315. https:\/\/doi.org\/10.1016\/j.cyto.2013.07.024","journal-title":"Cytokine"},{"key":"6643_CR51","doi-asserted-by":"publisher","unstructured":"Adekoya TO, Richardson RM. Cytokines and chemokines as mediators of prostate Cancer metastasis. Int J Mol Sci. 2020;21. https:\/\/doi.org\/10.3390\/ijms21124449","DOI":"10.3390\/ijms21124449"},{"key":"6643_CR52","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1186\/s13046-019-1461-z","volume":"38","author":"D Baci","year":"2019","unstructured":"Baci D, Bruno A, Cascini C, Gallazzi M, Mortara L, Sessa F, Pelosi G, Albini A, Noonan DM. Acetyl-L-Carnitine downregulates invasion (CXCR4\/CXCL12, MMP-9) and angiogenesis (VEGF, CXCL8) pathways in prostate cancer cells: rationale for prevention and interception strategies. J Exp Clin Cancer Res. 2019;38:464. https:\/\/doi.org\/10.1186\/s13046-019-1461-z","journal-title":"J Exp Clin Cancer Res"},{"key":"6643_CR53","doi-asserted-by":"publisher","first-page":"R246","DOI":"10.1016\/j.cub.2020.01.031","volume":"30","author":"L Cassetta","year":"2020","unstructured":"Cassetta L, Pollard JW. Tumor-associated macrophages. Curr Biol. 2020;30:R246\u20138. https:\/\/doi.org\/10.1016\/j.cub.2020.01.031","journal-title":"Curr Biol"},{"key":"6643_CR54","doi-asserted-by":"publisher","unstructured":"Muteeb G, Khafaga DSR, El-Morsy MT, Farhan M, Aatif M, Hosney M. Targeting tumor-associated macrophages with nanocarrier-based treatment for breast cancer: A step toward developing innovative anti-cancer therapeutics. Heliyon. 2024;10. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e37217","DOI":"10.1016\/j.heliyon.2024.e37217"},{"key":"6643_CR55","doi-asserted-by":"publisher","unstructured":"Wang Y, Zhang S, Song Z, Ouyang L, Li Y. Anti-Angiogenesis maintenance therapy in newly diagnosed and relapsed ovarian cancer: A Meta-analysis of phase III randomized controlled trials. Front Pharmacol. 2021;12. https:\/\/doi.org\/10.3389\/fphar.2021.726278","DOI":"10.3389\/fphar.2021.726278"},{"key":"6643_CR56","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s12951-024-02622-1","volume":"22","author":"Y Gong","year":"2024","unstructured":"Gong Y, Gao W, Zhang J, Dong X, Zhu D, Ma G. Engineering nanoparticles-enabled tumor-associated macrophages repolarization and phagocytosis restoration for enhanced cancer immunotherapy. J Nanobiotechnol. 2024;22:341. https:\/\/doi.org\/10.1186\/s12951-024-02622-1","journal-title":"J Nanobiotechnol"},{"key":"6643_CR57","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.3892\/ijo.2013.2073","volume":"43","author":"A Sato","year":"2013","unstructured":"Sato A, Nagase H, Obinata D, Fujiwara K, Fukuda N, Soma M, Yamaguchi K, Kawata N, Takahashi S. Inhibition of MMP-9 using a pyrrole-imidazole polyamide reduces cell invasion in renal cell carcinoma. Int J Oncol. 2013;43:1441\u20136. https:\/\/doi.org\/10.3892\/ijo.2013.2073","journal-title":"Int J Oncol"},{"key":"6643_CR58","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1515\/biol-2019-0052","volume":"14","author":"SL Beesetti","year":"2019","unstructured":"Beesetti SL, Jayadev M, Subhashini GV, Mansour L, Alwasel S, Harrath AH. Andrographolide as a therapeutic agent against breast and ovarian cancers. Open Life Sci. 2019;14:462\u20139. https:\/\/doi.org\/10.1515\/biol-2019-0052","journal-title":"Open Life Sci"},{"key":"6643_CR59","doi-asserted-by":"publisher","unstructured":"Ran X-M, Yang J, Wang Z-Y, Xiao L-Z, Deng Y-P, Zhang K-Q. M2 macrophage-derived Exosomal circTMCO3 acts through miR-515-5p and ITGA8 to enhance malignancy in ovarian cancer. Commun Biology. 2024;7. https:\/\/doi.org\/10.1038\/s42003-024-06095-8","DOI":"10.1038\/s42003-024-06095-8"},{"key":"6643_CR60","doi-asserted-by":"publisher","first-page":"5708","DOI":"10.1158\/0008-5472.CAN-06-4375","volume":"67","author":"TM Robinson-Smith","year":"2007","unstructured":"Robinson-Smith TM, Isaacsohn I, Mercer CA, Zhou M, Van Rooijen N, Husseinzadeh N, McFarland-Mancini MM, Drew AF. Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Cancer Res. 2007;67:5708\u201316. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-4375","journal-title":"Cancer Res"},{"key":"6643_CR61","doi-asserted-by":"publisher","first-page":"4157","DOI":"10.1172\/JCI87252","volume":"126","author":"M Yin","year":"2016","unstructured":"Yin M, Li X, Tan S, Zhou HJ, Ji W, Bellone S, Xu X, Zhang H, Santin AD, Lou G, Min W. Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer. J Clin Invest. 2016;126:4157\u201373. https:\/\/doi.org\/10.1172\/JCI87252","journal-title":"J Clin Invest"},{"key":"6643_CR62","doi-asserted-by":"publisher","first-page":"5127","DOI":"10.1038\/s41388-018-0317-x","volume":"37","author":"S Al Habyan","year":"2018","unstructured":"Al Habyan S, Kalos C, Szymborski J, McCaffrey L. Multicellular detachment generates metastatic spheroids during intra-abdominal dissemination in epithelial ovarian cancer. Oncogene. 2018;37:5127\u201335. https:\/\/doi.org\/10.1038\/s41388-018-0317-x","journal-title":"Oncogene"},{"key":"6643_CR63","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1158\/0008-5472.CAN-17-3341","volume":"78","author":"MJ Carroll","year":"2018","unstructured":"Carroll MJ, Fogg KC, Patel HA, Krause HB, Mancha AS, Patankar MS, Weisman PS, Barroilhet L, Kreeger PK. Alternatively-Activated macrophages upregulate mesothelial expression of P-Selectin to enhance adhesion of ovarian Cancer cells. Cancer Res. 2018;78:3560\u201373. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-3341","journal-title":"Cancer Res"},{"key":"6643_CR64","doi-asserted-by":"publisher","first-page":"4742","DOI":"10.1158\/0008-5472.CAN-14-3373","volume":"75","author":"DL Moughon","year":"2015","unstructured":"Moughon DL, He H, Schokrpur S, Jiang ZK, Yaqoob M, David J, Lin C, Iruela-Arispe ML, Dorigo O, Wu L. Macrophage Blockade using CSF1R inhibitors reverses the vascular leakage underlying malignant Ascites in Late-Stage epithelial ovarian Cancer. Cancer Res. 2015;75:4742\u201352. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-3373","journal-title":"Cancer Res"},{"key":"6643_CR65","doi-asserted-by":"publisher","unstructured":"Schweer D, Anand N, Anderson A, McCorkle JR, Neupane K, Nail AN, Harvey B, Hill KS, Ueland F, Richards C, Kolesar J. Human macrophage-engineered vesicles for utilization in ovarian cancer treatment. Frontiers in Oncology. 2023;12. https:\/\/doi.org\/10.3389\/fonc.2022.1042730","DOI":"10.3389\/fonc.2022.1042730"},{"key":"6643_CR66","doi-asserted-by":"publisher","unstructured":"Goncales NG, Goncalves BOP, Silva LM, da Silva Filho AL, and da, Conceicao Braga L. TNFRSF10D expression as a potential biomarker for cisplatin-induced damage and ovarian tumor relapse prediction. Pathol Res Pract. 2024;263:155592. https:\/\/doi.org\/10.1016\/j.prp.2024.155592","DOI":"10.1016\/j.prp.2024.155592"},{"key":"6643_CR67","doi-asserted-by":"publisher","unstructured":"Nakamura K, Smyth MJ. TREM2 marks tumor-associated macrophages. Signal Transduct Target Therapy. 2020;5. https:\/\/doi.org\/10.1038\/s41392-020-00356-8","DOI":"10.1038\/s41392-020-00356-8"},{"key":"6643_CR68","doi-asserted-by":"publisher","unstructured":"Nath N, Kashfi K. Tumor associated macrophages and \u2018NO\u2019. Biochem Pharmacol. 2020;176. https:\/\/doi.org\/10.1016\/j.bcp.2020.113899","DOI":"10.1016\/j.bcp.2020.113899"},{"key":"6643_CR69","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1631\/jzus.B2100029","volume":"22","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Zhang B, Zhang Q, Ma X, Feng H. Tumor-associated macrophages in osteosarcoma. J Zhejiang University-SCIENCE B. 2021;22:885\u201392. https:\/\/doi.org\/10.1631\/jzus.B2100029","journal-title":"J Zhejiang University-SCIENCE B"},{"key":"6643_CR70","doi-asserted-by":"publisher","first-page":"104769","DOI":"10.1016\/j.dci.2023.104769","volume":"147","author":"K Li","year":"2023","unstructured":"Li K, Wei X, Yang J. Cytokine networks that suppress fish cellular immunity. Dev Comp Immunol. 2023;147:104769. https:\/\/doi.org\/10.1016\/j.dci.2023.104769","journal-title":"Dev Comp Immunol"},{"key":"6643_CR71","doi-asserted-by":"publisher","first-page":"42","DOI":"10.16250\/j.32.1374.2017225","volume":"30","author":"Q Qian-Qian","year":"2018","unstructured":"Qian-Qian Q, Xiao-Fan W, Li-Na Z, Li-Yang D, Ji-Feng Z, Xiao-Jun C, Zhi-Peng X, Ya-Lin L, Feng L, Sha Z, Chuan S. [Schistosoma Japonicum heat shock protein 60 enhances regulatory T cell immunosuppressive function by promoting the expressions of IL-10 and TGF-beta]. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2018;30:42\u20136. https:\/\/doi.org\/10.16250\/j.32.1374.2017225","journal-title":"Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi"},{"key":"6643_CR72","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1080\/21645515.2018.1431598","volume":"14","author":"C Thepmalee","year":"2018","unstructured":"Thepmalee C, Panya A, Junking M, Chieochansin T, Yenchitsomanus PT. Inhibition of IL-10 and TGF-beta receptors on dendritic cells enhances activation of effector T-cells to kill cholangiocarcinoma cells. Hum Vaccin Immunother. 2018;14:1423\u201331. https:\/\/doi.org\/10.1080\/21645515.2018.1431598","journal-title":"Hum Vaccin Immunother"},{"key":"6643_CR73","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.cortex.2019.05.014","volume":"120","author":"Y Chen","year":"2019","unstructured":"Chen Y, Chen K, Ding J, Zhang Y, Yang Q, Lv Y, Guo Q, Han Z. Neural substrates of amodal and modality-specific semantic processing within the Temporal lobe: A lesion-behavior mapping study of semantic dementia. Cortex. 2019;120:78\u201391. https:\/\/doi.org\/10.1016\/j.cortex.2019.05.014","journal-title":"Cortex"},{"key":"6643_CR74","doi-asserted-by":"publisher","unstructured":"van Dalen FJ, van Stevendaal M, Fennemann FL, Verdoes M, Ilina O. Molecular repolarisation of Tumour-Associated macrophages. Molecules. 2018;24. https:\/\/doi.org\/10.3390\/molecules24010009","DOI":"10.3390\/molecules24010009"},{"key":"6643_CR75","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/nm1093","volume":"10","author":"TJ Curiel","year":"2004","unstructured":"Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942\u20139. https:\/\/doi.org\/10.1038\/nm1093","journal-title":"Nat Med"},{"key":"6643_CR76","doi-asserted-by":"publisher","unstructured":"Baradaran A, Asadzadeh Z, Hemmat N, Baghbanzadeh A, Shadbad MA, Khosravi N, Derakhshani A, Alemohammad H, Afrashteh Nour M, Safarpour H, et al. The cross-talk between tumor-associated macrophages and tumor endothelium: recent advances in macrophage-based cancer immunotherapy. Biomed Pharmacother. 2022;146. https:\/\/doi.org\/10.1016\/j.biopha.2021.112588","DOI":"10.1016\/j.biopha.2021.112588"},{"key":"6643_CR77","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41586-019-1456-0","volume":"572","author":"AA Barkal","year":"2019","unstructured":"Barkal AA, Brewer RE, Markovic M, Kowarsky M, Barkal SA, Zaro BW, Krishnan V, Hatakeyama J, Dorigo O, Barkal LJ, Weissman IL. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. 2019;572:392\u20136. https:\/\/doi.org\/10.1038\/s41586-019-1456-0","journal-title":"Nature"},{"key":"6643_CR78","doi-asserted-by":"publisher","first-page":"39021","DOI":"10.18632\/oncotarget.16547","volume":"8","author":"R Liu","year":"2017","unstructured":"Liu R, Wei H, Gao P, Yu H, Wang K, Fu Z, Ju B, Zhao M, Dong S, Li Z, et al. CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis. Oncotarget. 2017;8:39021\u201332. https:\/\/doi.org\/10.18632\/oncotarget.16547","journal-title":"Oncotarget"},{"key":"6643_CR79","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1172\/JCI120803","volume":"128","author":"H Lin","year":"2018","unstructured":"Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, Szeliga W, Herbst R, Harms PW, Fecher LA, et al. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. J Clin Invest. 2018;128:1708. https:\/\/doi.org\/10.1172\/JCI120803","journal-title":"J Clin Invest"},{"key":"6643_CR80","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/cac2.12157","volume":"41","author":"Y Yang","year":"2021","unstructured":"Yang Y, Xia L, Wu Y, Zhou H, Chen X, Li H, Xu M, Qi Z, Wang Z, Sun H, Cheng X. Programmed death ligand-1 regulates angiogenesis and metastasis by participating in the c\u2010JUN\/VEGFR2 signaling axis in ovarian cancer. Cancer Commun. 2021;41:511\u201327. https:\/\/doi.org\/10.1002\/cac2.12157","journal-title":"Cancer Commun"},{"key":"6643_CR81","doi-asserted-by":"publisher","unstructured":"Jochum F, Dumas E, Gougis P, Hamy AS, Querleu D, Lecointre L, Gaillard T, Reyal F, Lecuru F, Laas E, Akladios C. Survival outcomes of primary vs interval cytoreductive surgery for international federation of gynecology and obstetrics stage IV ovarian cancer: a nationwide population-based target trial emulation. Am J Obstet Gynecol. 2025;232(194 e191\u2013194 e111). https:\/\/doi.org\/10.1016\/j.ajog.2024.07.044","DOI":"10.1016\/j.ajog.2024.07.044"},{"key":"6643_CR82","first-page":"723","volume":"18","author":"A Straubhar","year":"2020","unstructured":"Straubhar A, Chi DS, Long Roche K. Update on the role of surgery in the management of advanced epithelial ovarian cancer. Clin Adv Hematol Oncol. 2020;18:723\u201331.","journal-title":"Clin Adv Hematol Oncol"},{"key":"6643_CR83","doi-asserted-by":"publisher","unstructured":"Gaumond SI, Beraja GE, Kamholtz I, Ferrari LM, Mahmoud RH, Jimenez JJ. Chemotherapy-Induced alopecia in ovarian cancer: incidence, mechanisms, and impact across treatment regimens. Cancers (Basel). 2025;17. https:\/\/doi.org\/10.3390\/cancers17030411","DOI":"10.3390\/cancers17030411"},{"key":"6643_CR84","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"6643_CR85","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1158\/0008-5472.CAN-22-0455","volume":"82","author":"LM Chambers","year":"2022","unstructured":"Chambers LM, Esakov Rhoades EL, Bharti R, Braley C, Tewari S, Trestan L, Alali Z, Bayik D, Lathia JD, Sangwan N, et al. Disruption of the gut microbiota confers cisplatin resistance in epithelial ovarian Cancer. Cancer Res. 2022;82:4654\u201369. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-0455","journal-title":"Cancer Res"},{"key":"6643_CR86","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1111\/jcmm.17802","volume":"27","author":"L Chi","year":"2023","unstructured":"Chi L, Huan L, Zhang C, Wang H, Lu J. Adenosine receptor A2b confers ovarian cancer survival and PARP inhibitor resistance through IL-6-STAT3 signalling. J Cell Mol Med. 2023;27:2150\u201364. https:\/\/doi.org\/10.1111\/jcmm.17802","journal-title":"J Cell Mol Med"},{"key":"6643_CR87","doi-asserted-by":"publisher","unstructured":"Lee AH, Mejia Pena C, Dawson MR. Comparing the secretomes of chemorefractory and chemoresistant ovarian Cancer cell populations. Cancers (Basel). 2022;14. https:\/\/doi.org\/10.3390\/cancers14061418","DOI":"10.3390\/cancers14061418"},{"key":"6643_CR88","doi-asserted-by":"publisher","unstructured":"Tang X, Ma C, Wu Q, Yu M. Ovarian cancer derived extracellular vesicles promote the cancer progression and angiogenesis by mediating M2 macrophages polarization. J Ovarian Res. 2024;17. https:\/\/doi.org\/10.1186\/s13048-024-01497-y","DOI":"10.1186\/s13048-024-01497-y"},{"key":"6643_CR89","doi-asserted-by":"publisher","unstructured":"Yousefzadeh Y, Hallaj S, Baghi Moornani M, Asghary A, Azizi G, Hojjat-Farsangi M, Ghalamfarsa G, Jadidi-Niaragh F. Tumor associated macrophages in the molecular pathogenesis of ovarian cancer. International Immunopharmacology. 2020;84. https:\/\/doi.org\/10.1016\/j.intimp.2020.106471","DOI":"10.1016\/j.intimp.2020.106471"},{"key":"6643_CR90","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s10585-023-10243-5","volume":"41","author":"A Deo","year":"2024","unstructured":"Deo A, Sleeman JP, Shaked Y. The role of host response to chemotherapy: resistance, metastasis and clinical implications. Clin Exp Metastasis. 2024;41:495\u2013507. https:\/\/doi.org\/10.1007\/s10585-023-10243-5","journal-title":"Clin Exp Metastasis"},{"key":"6643_CR91","doi-asserted-by":"publisher","first-page":"e2201095","DOI":"10.1002\/adma.202201095","volume":"34","author":"R Pattipeiluhu","year":"2022","unstructured":"Pattipeiluhu R, Arias-Alpizar G, Basha G, Chan KYT, Bussmann J, Sharp TH, Moradi MA, Sommerdijk N, Harris EN, Cullis PR, et al. Anionic lipid nanoparticles preferentially deliver mRNA to the hepatic reticuloendothelial system. Adv Mater. 2022;34:e2201095. https:\/\/doi.org\/10.1002\/adma.202201095","journal-title":"Adv Mater"},{"key":"6643_CR92","doi-asserted-by":"publisher","unstructured":"Boso D, Tognon M, Curtarello M, Minuzzo S, Piga I, Brillo V, Lazzarini E, Carlet J, Marra L, Trento C, et al. Anti-VEGF therapy selects for clones resistant to glucose starvation in ovarian cancer xenografts. J Exp Clin Cancer Res. 2023;42. https:\/\/doi.org\/10.1186\/s13046-023-02779-x","DOI":"10.1186\/s13046-023-02779-x"},{"key":"6643_CR93","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.ccell.2021.08.005","volume":"39","author":"L Sun","year":"2021","unstructured":"Sun L, Kees T, Almeida AS, Liu B, He XY, Ng D, Han X, Spector DL, McNeish IA, Gimotty P, et al. Activating a collaborative innate-adaptive immune response to control metastasis. Cancer Cell. 2021;39:1361\u2013e13741369. https:\/\/doi.org\/10.1016\/j.ccell.2021.08.005","journal-title":"Cancer Cell"},{"key":"6643_CR94","doi-asserted-by":"publisher","unstructured":"Nowak M, Klink M. The Role of Tumor-Associated Macrophages in the Progression and Chemoresistance of Ovarian Cancer. Cells. 2020;9. https:\/\/doi.org\/10.3390\/cells9051299","DOI":"10.3390\/cells9051299"},{"key":"6643_CR95","doi-asserted-by":"publisher","first-page":"109844","DOI":"10.1016\/j.celrep.2021.109844","volume":"37","author":"M Binnewies","year":"2021","unstructured":"Binnewies M, Pollack JL, Rudolph J, Dash S, Abushawish M, Lee T, Jahchan NS, Canaday P, Lu E, Norng M, et al. Targeting TREM2 on tumor-associated macrophages enhances immunotherapy. Cell Rep. 2021;37:109844. https:\/\/doi.org\/10.1016\/j.celrep.2021.109844","journal-title":"Cell Rep"},{"key":"6643_CR96","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/cei\/uxab020","volume":"209","author":"G Osborn","year":"2022","unstructured":"Osborn G, Stavraka C, Adams R, Sayasneh A, Ghosh S, Montes A, Lacy KE, Kristeleit R, Spicer J, Josephs DH, et al. Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies. Clin Exp Immunol. 2022;209:4\u201321. https:\/\/doi.org\/10.1093\/cei\/uxab020","journal-title":"Clin Exp Immunol"},{"key":"6643_CR97","doi-asserted-by":"publisher","first-page":"690201","DOI":"10.3389\/fimmu.2021.690201","volume":"12","author":"L Ardighieri","year":"2021","unstructured":"Ardighieri L, Missale F, Bugatti M, Gatta LB, Pezzali I, Monti M, Gottardi S, Zanotti L, Bignotti E, Ravaggi A, et al. Infiltration by CXCL10 secreting macrophages is associated with antitumor immunity and response to therapy in ovarian Cancer subtypes. Front Immunol. 2021;12:690201. https:\/\/doi.org\/10.3389\/fimmu.2021.690201","journal-title":"Front Immunol"},{"key":"6643_CR98","doi-asserted-by":"publisher","first-page":"6298","DOI":"10.1038\/s41467-020-20140-0","volume":"11","author":"M Song","year":"2020","unstructured":"Song M, Yeku OO, Rafiq S, Purdon T, Dong X, Zhu L, Zhang T, Wang H, Yu Z, Mai J, et al. Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages. Nat Commun. 2020;11:6298. https:\/\/doi.org\/10.1038\/s41467-020-20140-0","journal-title":"Nat Commun"},{"key":"6643_CR99","doi-asserted-by":"publisher","first-page":"152811","DOI":"10.1016\/j.imbio.2024.152811","volume":"229","author":"X Zhong","year":"2024","unstructured":"Zhong X, Zhang F, Xiao H, Tu R. Single-cell transcriptome analysis of macrophage subpopulations contributing to chemotherapy resistance in ovarian cancer. Immunobiology. 2024;229:152811. https:\/\/doi.org\/10.1016\/j.imbio.2024.152811","journal-title":"Immunobiology"},{"key":"6643_CR100","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1158\/0008-5472.CAN-12-3542","volume":"73","author":"EM Dijkgraaf","year":"2013","unstructured":"Dijkgraaf EM, Heusinkveld M, Tummers B, Vogelpoel LT, Goedemans R, Jha V, Nortier JW, Welters MJ, Kroep JR, van der Burg SH. Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer Res. 2013;73:2480\u201392. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-3542","journal-title":"Cancer Res"},{"key":"6643_CR101","doi-asserted-by":"publisher","first-page":"C721","DOI":"10.1152\/ajpcell.00461.2022","volume":"325","author":"DE Jazwinska","year":"2023","unstructured":"Jazwinska DE, Kulawiec DG, Zervantonakis IK. Cancer-mesothelial and cancer-macrophage interactions in the ovarian cancer microenvironment. Am J Physiol Cell Physiol. 2023;325:C721\u201330. https:\/\/doi.org\/10.1152\/ajpcell.00461.2022","journal-title":"Am J Physiol Cell Physiol"},{"key":"6643_CR102","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.canlet.2019.12.024","volume":"472","author":"W Liu","year":"2020","unstructured":"Liu W, Wang W, Wang X, Xu C, Zhang N, Di W. Cisplatin-stimulated macrophages promote ovarian cancer migration via the CCL20-CCR6 axis. Cancer Lett. 2020;472:59\u201369. https:\/\/doi.org\/10.1016\/j.canlet.2019.12.024","journal-title":"Cancer Lett"},{"key":"6643_CR103","doi-asserted-by":"publisher","first-page":"e18525","DOI":"10.1111\/jcmm.18525","volume":"28","author":"F Liu","year":"2024","unstructured":"Liu F, Zhang J, Gu X, Guo Q, Guo W. Single-cell transcriptome sequencing reveals SPP1-CD44-mediated macrophage-tumor cell interactions drive chemoresistance in TNBC. J Cell Mol Med. 2024;28:e18525. https:\/\/doi.org\/10.1111\/jcmm.18525","journal-title":"J Cell Mol Med"},{"key":"6643_CR104","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s12672-024-01614-9","volume":"15","author":"X Jin","year":"2024","unstructured":"Jin X, Tian Y, Zhu H, Sun Y, Zhang Z. Computer-aided analysis reveals metallothionein-positive cancer-associated fibroblasts promote angiogenesis in gastric adenocarcinoma. Discov Oncol. 2024;15:751. https:\/\/doi.org\/10.1007\/s12672-024-01614-9","journal-title":"Discov Oncol"},{"key":"6643_CR105","first-page":"1061","volume":"20","author":"MM Baekelandt","year":"2000","unstructured":"Baekelandt MM, Holm R, Nesland JM, Trope CG, Kristensen GB. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. Anticancer Res. 2000;20:1061\u20137.","journal-title":"Anticancer Res"},{"key":"6643_CR106","doi-asserted-by":"publisher","unstructured":"Murphy B, Miyamoto T, S Manning B, Mirji G, Ugolini A, Kannan T, Hamada K, Zhu Y, T Claiborne D, Huang L, et al., et al. Myeloid activation clears Ascites and reveals IL27-dependent regression of metastatic ovarian cancer. J Exp Med. 2024;221. https:\/\/doi.org\/10.1084\/jem.20231967","DOI":"10.1084\/jem.20231967"},{"key":"6643_CR107","doi-asserted-by":"publisher","first-page":"113474","DOI":"10.1016\/j.biopha.2022.113474","volume":"153","author":"YI Yang","year":"2022","unstructured":"Yang YI, Wang YY, Ahn JH, Kim BH, Choi JH. CCL2 overexpression is associated with Paclitaxel resistance in ovarian cancer cells via autocrine signaling and macrophage recruitment. Biomed Pharmacother. 2022;153:113474. https:\/\/doi.org\/10.1016\/j.biopha.2022.113474","journal-title":"Biomed Pharmacother"},{"key":"6643_CR108","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1158\/0008-5472.CAN-22-3260","volume":"83","author":"K Cao","year":"2023","unstructured":"Cao K, Zhang G, Yang M, Wang Y, He M, Zhang C, Huang Y, Lu J, Liu H. Attenuation of sialylation augments antitumor immunity and improves response to immunotherapy in ovarian Cancer. Cancer Res. 2023;83:2171\u201386. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-3260","journal-title":"Cancer Res"},{"key":"6643_CR109","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1556\/018.69.2018.4.3","volume":"69","author":"T Babic","year":"2018","unstructured":"Babic T, Dinic J, Buric SS, Hadzic S, Pesic M, Radojkovic D, Rankov AD. Comparative toxicity evaluation of targeted anticancer therapeutics in embryonic zebrafish and sea urchin models. Acta Biol Hung. 2018;69:395\u2013410. https:\/\/doi.org\/10.1556\/018.69.2018.4.3","journal-title":"Acta Biol Hung"},{"key":"6643_CR110","doi-asserted-by":"publisher","first-page":"123297","DOI":"10.1016\/j.lfs.2024.123297","volume":"361","author":"ZG Chen","year":"2025","unstructured":"Chen ZG, Xie YT, Yang C, Xiao T, Chen SY, Wu JH, Guo QN, Gao L. M2 macrophages secrete CCL20 to regulate iron metabolism and promote Daunorubicin resistance in AML cells. Life Sci. 2025;361:123297. https:\/\/doi.org\/10.1016\/j.lfs.2024.123297","journal-title":"Life Sci"},{"key":"6643_CR111","doi-asserted-by":"publisher","unstructured":"Spek CA, Aberson HL, Duitman J. Macrophage C\/EBPdelta drives gemcitabine, but not 5-FU or Paclitaxel, resistance of pancreatic Cancer cells in a Deoxycytidine-Dependent manner. Biomedicines. 2022;10. https:\/\/doi.org\/10.3390\/biomedicines10020219","DOI":"10.3390\/biomedicines10020219"},{"key":"6643_CR112","doi-asserted-by":"publisher","unstructured":"Li L, He D, Guo Q, Zhang Z, Ru D, Wang L, Gong K, Liu F, Duan Y, Li H. Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 conspicuously overcomes chemoresistant ovarian cancer. J Nanobiotechnol. 2022;20. https:\/\/doi.org\/10.1186\/s12951-022-01264-5","DOI":"10.1186\/s12951-022-01264-5"},{"key":"6643_CR113","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1111\/cas.14599","volume":"111","author":"K Yoshida","year":"2020","unstructured":"Yoshida K, Yokoi A, Kato T, Ochiya T, Yamamoto Y. The clinical impact of intra- and extracellular MiRNAs in ovarian cancer. Cancer Sci. 2020;111:3435\u201344. https:\/\/doi.org\/10.1111\/cas.14599","journal-title":"Cancer Sci"},{"key":"6643_CR114","doi-asserted-by":"publisher","unstructured":"Zhu X, Shen H, Yin X, Yang M, Wei H, Chen Q, Feng F, Liu Y, Xu W, Li Y. Macrophages derived exosomes deliver miR-223 to epithelial ovarian cancer cells to elicit a chemoresistant phenotype. J Exp Clin Cancer Res. 2019;38. https:\/\/doi.org\/10.1186\/s13046-019-1095-1","DOI":"10.1186\/s13046-019-1095-1"},{"key":"6643_CR115","doi-asserted-by":"publisher","first-page":"105166","DOI":"10.1016\/j.micpath.2021.105166","volume":"160","author":"W Zhang","year":"2021","unstructured":"Zhang W, Yuan Y, Li S, Deng B, Zhang J, Li Z. Comparative transcription analysis of resistant mutants against four different antibiotics in Pseudomonas aeruginosa. Microb Pathog. 2021;160:105166. https:\/\/doi.org\/10.1016\/j.micpath.2021.105166","journal-title":"Microb Pathog"},{"key":"6643_CR116","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/j.1442-2042.2011.02933.x","volume":"19","author":"T Yamane","year":"2012","unstructured":"Yamane T, Enokida H, Hayami H, Kawahara M, Nakagawa M. Genome-wide transcriptome analysis of fluoroquinolone resistance in clinical isolates of Escherichia coli. Int J Urol. 2012;19:360\u20138. https:\/\/doi.org\/10.1111\/j.1442-2042.2011.02933.x","journal-title":"Int J Urol"},{"key":"6643_CR117","doi-asserted-by":"publisher","first-page":"15541","DOI":"10.1038\/s41598-022-19897-9","volume":"12","author":"S Heo","year":"2022","unstructured":"Heo S, Kim T, Na HE, Lee G, Lee JH, Jeong DW. Transcriptomic analysis of Staphylococcus equorum KM1031 from the high-salt fermented seafood Jeotgal under Chloramphenicol, erythromycin and Lincomycin stresses. Sci Rep. 2022;12:15541. https:\/\/doi.org\/10.1038\/s41598-022-19897-9","journal-title":"Sci Rep"},{"key":"6643_CR118","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1158\/1535-7163.MCT-14-0969","volume":"14","author":"T Voloshin","year":"2015","unstructured":"Voloshin T, Alishekevitz D, Kaneti L, Miller V, Isakov E, Kaplanov I, Voronov E, Fremder E, Benhar M, Machluf M, et al. Blocking IL1beta pathway following Paclitaxel chemotherapy slightly inhibits primary tumor growth but promotes spontaneous metastasis. Mol Cancer Ther. 2015;14:1385\u201394. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0969","journal-title":"Mol Cancer Ther"},{"key":"6643_CR119","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s12935-022-02717-5","volume":"22","author":"P Su","year":"2022","unstructured":"Su P, Jiang L, Zhang Y, Yu T, Kang W, Liu Y, Yu J. Crosstalk between tumor-associated macrophages and tumor cells promotes chemoresistance via CXCL5\/PI3K\/AKT\/mTOR pathway in gastric cancer. Cancer Cell Int. 2022;22:290. https:\/\/doi.org\/10.1186\/s12935-022-02717-5","journal-title":"Cancer Cell Int"},{"key":"6643_CR120","doi-asserted-by":"publisher","first-page":"e12996","DOI":"10.1111\/aji.12996","volume":"80","author":"A Mlynska","year":"2018","unstructured":"Mlynska A, Povilaityte E, Zemleckaite I, Zilionyte K, Strioga M, Krasko J, Dobrovolskiene N, Peng MW, Intaite B, Pasukoniene V. Platinum sensitivity of ovarian cancer cells does not influence their ability to induce M2-type macrophage polarization. Am J Reprod Immunol. 2018;80:e12996. https:\/\/doi.org\/10.1111\/aji.12996","journal-title":"Am J Reprod Immunol"},{"key":"6643_CR121","doi-asserted-by":"publisher","first-page":"114011","DOI":"10.1016\/j.intimp.2024.114011","volume":"147","author":"M Li","year":"2025","unstructured":"Li M, Tian Y, Si L, Fu H, Lai T, Guo R. OTUD4-mediated Inhibition of YAP1 signaling pathway in ovarian cancer: implications for macrophage polarization and recruitment. Int Immunopharmacol. 2025;147:114011. https:\/\/doi.org\/10.1016\/j.intimp.2024.114011","journal-title":"Int Immunopharmacol"},{"key":"6643_CR122","doi-asserted-by":"publisher","DOI":"10.1101\/2024.05.10.593562","author":"EN Tcyganov","year":"2024","unstructured":"Tcyganov EN, Kwak T, Yang X, Poli ANR, Hart C, Bhuniya A, Cassel J, Kossenkov A, Auslander N, Lu L, et al. Targeting LxCxE cleft pocket of retinoblastoma protein in M2 macrophages inhibits ovarian cancer progression. BioRxiv. 2024. https:\/\/doi.org\/10.1101\/2024.05.10.593562","journal-title":"BioRxiv"},{"key":"6643_CR123","doi-asserted-by":"publisher","unstructured":"Yu M, Wu Y, Li Q, Hong W, Yang Y, Hu X, Yang Y, Lu T, Zhao X, Wei X. Colony-stimulating factor-1 receptor inhibition combined with paclitaxel exerts effective antitumor effects in the treatment of ovarian cancer. Genes & Diseases. 2024;11. https:\/\/doi.org\/10.1016\/j.gendis.2023.04.023","DOI":"10.1016\/j.gendis.2023.04.023"},{"key":"6643_CR124","doi-asserted-by":"publisher","unstructured":"Jeong M, Wang Y-Y, Choi J-Y, Lim MC, Choi J-H. CC Chemokine Ligand 7 Derived from Cancer-Stimulated Macrophages Promotes Ovarian Cancer Cell Invasion. Cancers. 2021;13. https:\/\/doi.org\/10.3390\/cancers13112745","DOI":"10.3390\/cancers13112745"},{"key":"6643_CR125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/5940049","volume":"2022","author":"J Li","year":"2022","unstructured":"Li J, Zhi X, Sun Y, Chen M, Yao L, Sun Y. The PDGF family is associated with activated tumor stroma and poor prognosis in ovarian Cancer. Dis Markers. 2022;2022:1\u201319. https:\/\/doi.org\/10.1155\/2022\/5940049","journal-title":"Dis Markers"},{"key":"6643_CR126","doi-asserted-by":"publisher","unstructured":"Beach C, MacLean D, Majorova D, Arnold JN, Olcina MM. The effects of radiation therapy on the macrophage response in cancer. Frontiers in Oncology. 2022;12. https:\/\/doi.org\/10.3389\/fonc.2022.1020606","DOI":"10.3389\/fonc.2022.1020606"},{"key":"6643_CR127","doi-asserted-by":"publisher","unstructured":"Li L, Tian Y. The role of metabolic reprogramming of tumor-associated macrophages in shaping the immunosuppressive tumor microenvironment. Biomedicine & Pharmacotherapy. 2023;161. https:\/\/doi.org\/10.1016\/j.biopha.2023.114504","DOI":"10.1016\/j.biopha.2023.114504"},{"key":"6643_CR128","first-page":"999","volume":"3","author":"SK Chambers","year":"1997","unstructured":"Chambers SK, Kacinski BM, Ivins CM, Carcangiu ML. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1. Clin Cancer Res. 1997;3:999\u20131007.","journal-title":"Clin Cancer Res"},{"key":"6643_CR129","doi-asserted-by":"publisher","unstructured":"Akkari L, Bowman RL, Tessier J, Klemm F, Handgraaf SM, de Groot M, Quail DF, Tillard L, Gadiot J, Huse JT et al. Dynamic changes in glioma macrophage populations after radiotherapy reveal CSF-1R inhibition as a strategy to overcome resistance. Sci Transl Med. 2020;12. https:\/\/doi.org\/10.1126\/scitranslmed.aaw7843","DOI":"10.1126\/scitranslmed.aaw7843"},{"key":"6643_CR130","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1158\/2326-6066.CIR-21-0326","volume":"10","author":"C Pfirschke","year":"2022","unstructured":"Pfirschke C, Zilionis R, Engblom C, Messemaker M, Zou AE, Rickelt S, Gort-Freitas NA, Lin Y, Bill R, Siwicki M, et al. Macrophage-Targeted therapy unlocks antitumoral Cross-talk between IFNgamma-Secreting lymphocytes and IL12-Producing dendritic cells. Cancer Immunol Res. 2022;10:40\u201355. https:\/\/doi.org\/10.1158\/2326-6066.CIR-21-0326","journal-title":"Cancer Immunol Res"},{"key":"6643_CR131","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.ccr.2014.05.016","volume":"25","author":"CH Ries","year":"2014","unstructured":"Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klaman I, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014;25:846\u201359. https:\/\/doi.org\/10.1016\/j.ccr.2014.05.016","journal-title":"Cancer Cell"},{"key":"6643_CR132","doi-asserted-by":"publisher","unstructured":"Machiels JP, Gomez-Roca C, Michot JM, Zamarin D, Mitchell T, Catala G, Eberst L, Jacob W, Jegg AM, Cannarile MA et al. Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients. J Immunother Cancer. 2020;8. https:\/\/doi.org\/10.1136\/jitc-2020-001153","DOI":"10.1136\/jitc-2020-001153"},{"key":"6643_CR133","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1007\/s10637-021-01088-4","volume":"39","author":"GS Falchook","year":"2021","unstructured":"Falchook GS, Peeters M, Rottey S, Dirix LY, Obermannova R, Cohen JE, Perets R, Frommer RS, Bauer TM, Wang JS, et al. A phase 1a\/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or Tremelimumab in patients with advanced solid tumors. Invest New Drugs. 2021;39:1284\u201397. https:\/\/doi.org\/10.1007\/s10637-021-01088-4","journal-title":"Invest New Drugs"},{"key":"6643_CR134","doi-asserted-by":"publisher","unstructured":"Qiu J, Ren T, Liu Q, Jiang Q, Wu T, Cheng LC, Yan W, Qu X, Han X, Hua K. Dissecting the Distinct Tumor Microenvironments of HRD and HRP Ovarian Cancer: Implications for Targeted Therapies to Overcome PARPi Resistance in HRD Tumors and Refractoriness in HRP Tumors. Advanced Science. 2024;11. https:\/\/doi.org\/10.1002\/advs.202309755","DOI":"10.1002\/advs.202309755"},{"key":"6643_CR135","doi-asserted-by":"publisher","first-page":"28697","DOI":"10.18632\/oncotarget.7376","volume":"7","author":"SY Lim","year":"2016","unstructured":"Lim SY, Yuzhalin AE, Gordon-Weeks AN, Muschel RJ. Targeting the CCL2-CCR2 signaling axis in cancer metastasis. Oncotarget. 2016;7:28697\u2013710. https:\/\/doi.org\/10.18632\/oncotarget.7376","journal-title":"Oncotarget"},{"key":"6643_CR136","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature10138","volume":"475","author":"BZ Qian","year":"2011","unstructured":"Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011;475:222\u20135. https:\/\/doi.org\/10.1038\/nature10138","journal-title":"Nature"},{"key":"6643_CR137","doi-asserted-by":"publisher","first-page":"3642","DOI":"10.1021\/acs.molpharmaceut.7b00997","volume":"15","author":"S Shen","year":"2018","unstructured":"Shen S, Zhang Y, Chen KG, Luo YL, Wang J. Cationic polymeric nanoparticle delivering CCR2 SiRNA to inflammatory monocytes for tumor microenvironment modification and Cancer therapy. Mol Pharm. 2018;15:3642\u201353. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00997","journal-title":"Mol Pharm"},{"key":"6643_CR138","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/bjc.2017.297","volume":"117","author":"X Wang","year":"2017","unstructured":"Wang X, Zhu Q, Lin Y, Wu L, Wu X, Wang K, He Q, Xu C, Wan X, Wang X. Crosstalk between TEMs and endothelial cells modulates angiogenesis and metastasis via IGF1-IGF1R signalling in epithelial ovarian cancer. Br J Cancer. 2017;117:1371\u201382. https:\/\/doi.org\/10.1038\/bjc.2017.297","journal-title":"Br J Cancer"},{"key":"6643_CR139","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1158\/1078-0432.CCR-17-1775","volume":"24","author":"DM Hyman","year":"2018","unstructured":"Hyman DM, Rizvi N, Natale R, Armstrong DK, Birrer M, Recht L, Dotan E, Makker V, Kaley T, Kuruvilla D, et al. Phase I study of MEDI3617, a selective Angiopoietin-2 inhibitor alone and combined with Carboplatin\/Paclitaxel, Paclitaxel, or bevacizumab for advanced solid tumors. Clin Cancer Res. 2018;24:2749\u201357. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1775","journal-title":"Clin Cancer Res"},{"key":"6643_CR140","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/S1470-2045(19)30178-0","volume":"20","author":"I Vergote","year":"2019","unstructured":"Vergote I, Scambia G, O\u2019Malley DM, Van Calster B, Park SY, Del Campo JM, Meier W, Bamias A, Colombo N, Wenham RM, et al. Trebananib or placebo plus carboplatin and Paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3\/ENGOT-ov2\/GOG-3001): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20:862\u201376. https:\/\/doi.org\/10.1016\/S1470-2045(19)30178-0","journal-title":"Lancet Oncol"},{"key":"6643_CR141","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-025-06755-3","author":"AL Huber","year":"2025","unstructured":"Huber AL, Bauer A, Beirer J, Frede K, Kirchmair K, Angermann R, Rehak M, Zehetner C, Nowosielski Y. Systemic counterregulatory response of angiopoietin-2 after intravitreal injections with faricimab for nAMD. Graefes Arch Clin Exp Ophthalmol. 2025. https:\/\/doi.org\/10.1007\/s00417-025-06755-3","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6643_CR142","doi-asserted-by":"publisher","unstructured":"Scheuer W, Thomas M, Hanke P, Sam J, Osl F, Weininger D, Baehner M, Seeber S, Kettenberger H, Schanzer J et al. Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2. MAbs. 2016;8:562\u2013573. https:\/\/doi.org\/10.1080\/19420862.2016.1147640","DOI":"10.1080\/19420862.2016.1147640"},{"key":"6643_CR143","doi-asserted-by":"publisher","first-page":"72147","DOI":"10.18632\/oncotarget.20046","volume":"8","author":"Y Kobayashi","year":"2017","unstructured":"Kobayashi Y, Kashima H, Rahmanto YS, Banno K, Yu Y, Matoba Y, Watanabe K, Iijima M, Takeda T, Kunitomi H, et al. Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer. Oncotarget. 2017;8:72147\u201356. https:\/\/doi.org\/10.18632\/oncotarget.20046","journal-title":"Oncotarget"},{"key":"6643_CR144","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.4161\/cbt.29184","volume":"15","author":"NM Reusser","year":"2014","unstructured":"Reusser NM, Dalton HJ, Pradeep S, Gonzalez-Villasana V, Jennings NB, Vasquez HG, Wen Y, Rupaimoole R, Nagaraja AS, Gharpure K, et al. Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer. Cancer Biol Ther. 2014;15:1061\u20137. https:\/\/doi.org\/10.4161\/cbt.29184","journal-title":"Cancer Biol Ther"},{"key":"6643_CR145","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ccr.2013.01.008","volume":"23","author":"G Germano","year":"2013","unstructured":"Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E, Uboldi S, Zucchetti M, Pasqualini F, et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell. 2013;23:249\u201362. https:\/\/doi.org\/10.1016\/j.ccr.2013.01.008","journal-title":"Cancer Cell"},{"key":"6643_CR146","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41467-021-20893-2","volume":"12","author":"A Rodriguez-Garcia","year":"2021","unstructured":"Rodriguez-Garcia A, Lynn RC, Poussin M, Eiva MA, Shaw LC, O\u2019Connor RS, Minutolo NG, Casado-Medrano V, Lopez G, Matsuyama T, Powell DJ Jr. CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy. Nat Commun. 2021;12:877. https:\/\/doi.org\/10.1038\/s41467-021-20893-2","journal-title":"Nat Commun"},{"key":"6643_CR147","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.cell.2020.07.013","volume":"182","author":"M Molgora","year":"2020","unstructured":"Molgora M, Esaulova E, Vermi W, Hou J, Chen Y, Luo J, Brioschi S, Bugatti M, Omodei AS, Ricci B, et al. TREM2 modulation remodels the tumor myeloid landscape enhancing Anti-PD-1 immunotherapy. Cell. 2020;182:886\u2013e900817. https:\/\/doi.org\/10.1016\/j.cell.2020.07.013","journal-title":"Cell"},{"key":"6643_CR148","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41571-022-00632-2","volume":"19","author":"MJ Pittet","year":"2022","unstructured":"Pittet MJ, Michielin O, Migliorini D. Author correction: clinical relevance of tumour-associated macrophages. Nat Rev Clin Oncol. 2022;19:424. https:\/\/doi.org\/10.1038\/s41571-022-00632-2","journal-title":"Nat Rev Clin Oncol"},{"key":"6643_CR149","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1007\/s00262-010-0914-1","volume":"59","author":"MA Geller","year":"2010","unstructured":"Geller MA, Cooley S, Argenta PA, Downs LS, Carson LF, Judson PL, Ghebre R, Weigel B, Panoskaltsis-Mortari A, Curtsinger J, Miller JS. Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers. Cancer Immunol Immunother. 2010;59:1877\u201384. https:\/\/doi.org\/10.1007\/s00262-010-0914-1","journal-title":"Cancer Immunol Immunother"},{"key":"6643_CR150","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1093\/annonc\/mdx049","volume":"28","author":"BJ Monk","year":"2017","unstructured":"Monk BJ, Brady MF, Aghajanian C, Lankes HA, Rizack T, Leach J, Fowler JM, Higgins R, Hanjani P, Morgan M, et al. A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a gynecologic oncology group partners study. Ann Oncol. 2017;28:996\u20131004. https:\/\/doi.org\/10.1093\/annonc\/mdx049","journal-title":"Ann Oncol"},{"key":"6643_CR151","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1021\/acs.bioconjchem.1c00139","volume":"32","author":"Y Kang","year":"2021","unstructured":"Kang Y, Flores L, Ngai HW, Cornejo YR, Haber T, McDonald M, Moreira DF, Gonzaga JM, Abidi W, Zhang Y, et al. Large, anionic liposomes enable targeted intraperitoneal delivery of a TLR 7\/8 agonist to repolarize ovarian tumors\u2019 microenvironment. Bioconjug Chem. 2021;32:1581\u201392. https:\/\/doi.org\/10.1021\/acs.bioconjchem.1c00139","journal-title":"Bioconjug Chem"},{"key":"6643_CR152","doi-asserted-by":"publisher","first-page":"704001","DOI":"10.3389\/fonc.2021.704001","volume":"11","author":"F Le","year":"2021","unstructured":"Le F, Yang L, Han Y, Zhong Y, Zhan F, Feng Y, Hu H, Chen T, Tan B. TPL inhibits the invasion and migration of Drug-Resistant ovarian Cancer by targeting the PI3K\/AKT\/NF-kappaB-Signaling pathway to inhibit the polarization of M2 TAMs. Front Oncol. 2021;11:704001. https:\/\/doi.org\/10.3389\/fonc.2021.704001","journal-title":"Front Oncol"},{"key":"6643_CR153","doi-asserted-by":"publisher","first-page":"622","DOI":"10.3978\/j.issn.1000-9604.2014.09.01","volume":"26","author":"C Meng","year":"2014","unstructured":"Meng C, Zhu H, Song H, Wang Z, Huang G, Li D, Ma Z, Ma J, Qin Q, Sun X, Ma J. Targets and molecular mechanisms of triptolide in cancer therapy. Chin J Cancer Res. 2014;26:622\u20136. https:\/\/doi.org\/10.3978\/j.issn.1000-9604.2014.09.01","journal-title":"Chin J Cancer Res"},{"key":"6643_CR154","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.smim.2009.05.011","volume":"21","author":"J Suttles","year":"2009","unstructured":"Suttles J, Stout RD. Macrophage CD40 signaling: a pivotal regulator of disease protection and pathogenesis. Semin Immunol. 2009;21:257\u201364. https:\/\/doi.org\/10.1016\/j.smim.2009.05.011","journal-title":"Semin Immunol"},{"key":"6643_CR155","doi-asserted-by":"publisher","first-page":"e23033","DOI":"10.4161\/onci.23033","volume":"2","author":"RH Vonderheide","year":"2013","unstructured":"Vonderheide RH, Burg JM, Mick R, Trosko JA, Li D, Shaik MN, Tolcher AW, Hamid O. Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and Paclitaxel in patients with advanced solid tumors. Oncoimmunology. 2013;2:e23033. https:\/\/doi.org\/10.4161\/onci.23033","journal-title":"Oncoimmunology"},{"key":"6643_CR156","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1158\/2326-6066.CIR-18-0805","volume":"7","author":"S Ye","year":"2019","unstructured":"Ye S, Cohen D, Belmar NA, Choi D, Tan SS, Sho M, Akamatsu Y, Kim H, Iyer R, Cabel J, et al. A bispecific molecule targeting CD40 and tumor antigen mesothelin enhances tumor-Specific immunity. Cancer Immunol Res. 2019;7:1864\u201375. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0805","journal-title":"Cancer Immunol Res"},{"key":"6643_CR157","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2019.02.006","volume":"35","author":"NF Kuhn","year":"2019","unstructured":"Kuhn NF, Purdon TJ, van Leeuwen DG, Lopez AV, Curran KJ, Daniyan AF, Brentjens RJ. CD40 Ligand-Modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response. Cancer Cell. 2019;35:473\u2013e488476. https:\/\/doi.org\/10.1016\/j.ccell.2019.02.006","journal-title":"Cancer Cell"},{"key":"6643_CR158","doi-asserted-by":"publisher","first-page":"5846","DOI":"10.1158\/1078-0432.CCR-17-0285","volume":"23","author":"E Eriksson","year":"2017","unstructured":"Eriksson E, Milenova I, Wenthe J, Stahle M, Leja-Jarblad J, Ullenhag G, Dimberg A, Moreno R, Alemany R, Loskog A. Shaping the tumor stroma and sparking immune activation by CD40 and 4-1BB signaling induced by an armed oncolytic virus. Clin Cancer Res. 2017;23:5846\u201357. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0285","journal-title":"Clin Cancer Res"},{"key":"6643_CR159","doi-asserted-by":"publisher","first-page":"758","DOI":"10.3389\/fcell.2020.00758","volume":"8","author":"Y Yang","year":"2020","unstructured":"Yang Y, Yang Y, Yang J, Zhao X, Wei X. Tumor microenvironment in ovarian cancer: function and therapeutic strategy. Front Cell Dev Biol. 2020;8:758. https:\/\/doi.org\/10.3389\/fcell.2020.00758","journal-title":"Front Cell Dev Biol"},{"key":"6643_CR160","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/ijc.24401","volume":"125","author":"D Duluc","year":"2009","unstructured":"Duluc D, Corvaisier M, Blanchard S, Catala L, Descamps P, Gamelin E, Ponsoda S, Delneste Y, Hebbar M, Jeannin P. Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int J Cancer. 2009;125:367\u201373. https:\/\/doi.org\/10.1002\/ijc.24401","journal-title":"Int J Cancer"},{"key":"6643_CR161","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/gt.2009.159","volume":"17","author":"K Anwer","year":"2010","unstructured":"Anwer K, Barnes MN, Fewell J, Lewis DH, Alvarez RD. Phase-I clinical trial of IL-12 plasmid\/lipopolymer complexes for the treatment of recurrent ovarian cancer. Gene Ther. 2010;17:360\u20139. https:\/\/doi.org\/10.1038\/gt.2009.159","journal-title":"Gene Ther"},{"key":"6643_CR162","doi-asserted-by":"publisher","unstructured":"Brempelis KJ, Cowan CM, Kreuser SA, Labadie KP, Prieskorn BM, Lieberman NAP, Ene CI, Moyes KW, Chinn H, DeGolier KR et al. Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses. J Immunother Cancer. 2020;8. https:\/\/doi.org\/10.1136\/jitc-2020-001356","DOI":"10.1136\/jitc-2020-001356"},{"key":"6643_CR163","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.eururo.2021.01.025","volume":"79","author":"M Santoni","year":"2021","unstructured":"Santoni M, Massari F, Santoni G, Cimadamore A, Montironi R, Battelli N. Re: human chimeric antigen receptor macrophages for Cancer immunotherapy. Eur Urol. 2021;79:887\u20139. https:\/\/doi.org\/10.1016\/j.eururo.2021.01.025","journal-title":"Eur Urol"},{"key":"6643_CR164","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41392-022-01131-7","volume":"7","author":"GN Li","year":"2022","unstructured":"Li GN, Zhao XJ, Wang Z, Luo MS, Shi SN, Yan DM, Li HY, Liu JH, Yang Y, Tan JH, et al. Elaiophylin triggers paraptosis and preferentially kills ovarian cancer drug-resistant cells by inducing MAPK hyperactivation. Signal Transduct Target Ther. 2022;7:317. https:\/\/doi.org\/10.1038\/s41392-022-01131-7","journal-title":"Signal Transduct Target Ther"},{"key":"6643_CR165","doi-asserted-by":"publisher","unstructured":"Mo Y, Leung LL, Mak CSL, Wang X, Chan WS, Hui LMN, Tang HWM, Siu MKY, Sharma R, Xu D, et al. Tumor-secreted Exosomal miR-141 activates tumor-stroma interactions and controls premetastatic niche formation in ovarian cancer metastasis. Mol Cancer. 2023;22. https:\/\/doi.org\/10.1186\/s12943-022-01703-9","DOI":"10.1186\/s12943-022-01703-9"},{"key":"6643_CR166","doi-asserted-by":"publisher","first-page":"6118","DOI":"10.1158\/0008-5472.CAN-16-1272","volume":"76","author":"J Walton","year":"2016","unstructured":"Walton J, Blagih J, Ennis D, Leung E, Dowson S, Farquharson M, Tookman LA, Orange C, Athineos D, Mason S, et al. CRISPR\/Cas9-Mediated Trp53 and Brca2 knockout to generate improved murine models of ovarian High-Grade serous carcinoma. Cancer Res. 2016;76:6118\u201329. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-1272","journal-title":"Cancer Res"},{"key":"6643_CR167","doi-asserted-by":"publisher","unstructured":"Zhang J, Li Y, Liu H, Zhang J, Wang J, Xia J, Zhang Y, Yu X, Ma J, Huang M, et al. Genome-wide CRISPR\/Cas9 library screen identifies PCMT1 as a critical driver of ovarian cancer metastasis. J Exp Clin Cancer Res. 2022;41. https:\/\/doi.org\/10.1186\/s13046-022-02242-3","DOI":"10.1186\/s13046-022-02242-3"},{"key":"6643_CR168","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1007\/s12033-023-00932-7","volume":"66","author":"C Aslan","year":"2024","unstructured":"Aslan C, Zolbanin NM, Faraji F, Jafari R. Exosomes for CRISPR-Cas9 delivery: the cutting edge in genome editing. Mol Biotechnol. 2024;66:3092\u2013116. https:\/\/doi.org\/10.1007\/s12033-023-00932-7","journal-title":"Mol Biotechnol"},{"key":"6643_CR169","doi-asserted-by":"publisher","unstructured":"Nie D, Guo T, Yue M, Li W, Zong X, Zhu Y, Huang J, Lin M. Research Progress on Nanoparticles-Based CRISPR\/Cas9 System for Targeted Therapy of Tumors. Biomolecules. 2022;12. https:\/\/doi.org\/10.3390\/biom12091239","DOI":"10.3390\/biom12091239"},{"key":"6643_CR170","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.1039\/d2bm01636b","volume":"11","author":"Z Iqbal","year":"2023","unstructured":"Iqbal Z, Rehman K, Xia J, Shabbir M, Zaman M, Liang Y, Duan L. Biomaterial-assisted targeted and controlled delivery of CRISPR\/Cas9 for precise gene editing. Biomater Sci. 2023;11:3762\u201383. https:\/\/doi.org\/10.1039\/d2bm01636b","journal-title":"Biomater Sci"},{"key":"6643_CR171","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2174\/0929866530666230607104453","volume":"30","author":"SAM Sherazi","year":"2023","unstructured":"Sherazi SAM, Rafique F, Haris M, Arshad A, Qaiser H, Uzair M, Arshad M. Applications of CRISPR Cas-9 in ovarian Cancer research. Protein Pept Lett. 2023;30:653\u201367. https:\/\/doi.org\/10.2174\/0929866530666230607104453","journal-title":"Protein Pept Lett"},{"key":"6643_CR172","doi-asserted-by":"publisher","unstructured":"Wang SW, Gao C, Zheng YM, Yi L, Lu JC, Huang XY, Cai JB, Zhang PF, Cui YH, Ke AW. Current applications and future perspective of CRISPR\/Cas9 gene editing in cancer. Mol Cancer. 2022;21. https:\/\/doi.org\/10.1186\/s12943-022-01518-8","DOI":"10.1186\/s12943-022-01518-8"},{"key":"6643_CR173","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.2147\/IJN.S507688","volume":"20","author":"HK Kim","year":"2025","unstructured":"Kim HK, Cheong H, Kim MY, Jin HE. Therapeutic targeting in ovarian cancer: Nano-Enhanced CRISPR\/Cas9 gene editing and drug combination therapy. Int J Nanomed. 2025;20:3907\u201331. https:\/\/doi.org\/10.2147\/IJN.S507688","journal-title":"Int J Nanomed"},{"key":"6643_CR174","doi-asserted-by":"publisher","first-page":"10872","DOI":"10.1021\/acsnano.3c02657","volume":"17","author":"Y Shang","year":"2023","unstructured":"Shang Y, Lu H, Liao L, Li S, Xiong H, Yao J. Bioengineered nanospores selectively blocking LC3-Associated phagocytosis in Tumor-Associated macrophages potentiate antitumor immunity. ACS Nano. 2023;17:10872\u201387. https:\/\/doi.org\/10.1021\/acsnano.3c02657","journal-title":"ACS Nano"},{"key":"6643_CR175","doi-asserted-by":"publisher","first-page":"18274","DOI":"10.1039\/d4nr02795g","volume":"16","author":"H Patni","year":"2024","unstructured":"Patni H, Chaudhary R, Kumar A. Unleashing nanotechnology to redefine tumor-associated macrophage dynamics and non-coding RNA crosstalk in breast cancer. Nanoscale. 2024;16:18274\u201394. https:\/\/doi.org\/10.1039\/d4nr02795g","journal-title":"Nanoscale"},{"key":"6643_CR176","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1016\/j.apsb.2022.02.008","volume":"12","author":"S Zhang","year":"2022","unstructured":"Zhang S, Xie F, Li K, Zhang H, Yin Y, Yu Y, Lu G, Zhang S, Wei Y, Xu K, et al. Gold nanoparticle-directed autophagy intervention for antitumor immunotherapy via inhibiting tumor-associated macrophage M2 polarization. Acta Pharm Sin B. 2022;12:3124\u201338. https:\/\/doi.org\/10.1016\/j.apsb.2022.02.008","journal-title":"Acta Pharm Sin B"},{"key":"6643_CR177","doi-asserted-by":"publisher","first-page":"e2003543","DOI":"10.1002\/smll.202003543","volume":"16","author":"L Liu","year":"2020","unstructured":"Liu L, Wang Y, Guo X, Zhao J, Zhou S. A biomimetic polymer magnetic nanocarrier polarizing Tumor-Associated macrophages for potentiating immunotherapy. Small. 2020;16:e2003543. https:\/\/doi.org\/10.1002\/smll.202003543","journal-title":"Small"},{"key":"6643_CR178","doi-asserted-by":"publisher","first-page":"eadg2697","DOI":"10.1126\/sciadv.adg2697","volume":"9","author":"S Han","year":"2023","unstructured":"Han S, Bao X, Zou Y, Wang L, Li Y, Yang L, Liao A, Zhang X, Jiang X, Liang D, et al. d-lactate modulates M2 tumor-associated macrophages and remodels immunosuppressive tumor microenvironment for hepatocellular carcinoma. Sci Adv. 2023;9:eadg2697. https:\/\/doi.org\/10.1126\/sciadv.adg2697","journal-title":"Sci Adv"},{"key":"6643_CR179","doi-asserted-by":"publisher","first-page":"5871","DOI":"10.1021\/acsabm.1c00461","volume":"4","author":"X Lin","year":"2021","unstructured":"Lin X, Fang Y, Jin X, Zhang M, Shi K. Modulating repolarization of Tumor-Associated macrophages with targeted therapeutic nanoparticles as a potential strategy for Cancer therapy. ACS Appl Bio Mater. 2021;4:5871\u201396. https:\/\/doi.org\/10.1021\/acsabm.1c00461","journal-title":"ACS Appl Bio Mater"},{"key":"6643_CR180","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.2147\/IJN.S93483","volume":"11","author":"RA Ortega","year":"2016","unstructured":"Ortega RA, Barham W, Sharman K, Tikhomirov O, Giorgio TD, Yull FE. Manipulating the NF-kappaB pathway in macrophages using mannosylated, siRNA-delivering nanoparticles can induce immunostimulatory and tumor cytotoxic functions. Int J Nanomed. 2016;11:2163\u201377. https:\/\/doi.org\/10.2147\/IJN.S93483","journal-title":"Int J Nanomed"},{"key":"6643_CR181","doi-asserted-by":"publisher","first-page":"96496","DOI":"10.18632\/oncotarget.20410","volume":"8","author":"YA Lyons","year":"2017","unstructured":"Lyons YA, Pradeep S, Wu SY, Haemmerle M, Hansen JM, Wagner MJ, Villar-Prados A, Nagaraja AS, Dood RL, Previs RA, et al. Macrophage depletion through colony stimulating factor 1 receptor pathway Blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget. 2017;8:96496\u2013505. https:\/\/doi.org\/10.18632\/oncotarget.20410","journal-title":"Oncotarget"},{"key":"6643_CR182","doi-asserted-by":"publisher","unstructured":"Jeong M, Wang YY, Choi JY, Lim MC, Choi JH. CC Chemokine Ligand 7 Derived from Cancer-Stimulated Macrophages Promotes Ovarian Cancer Cell Invasion. Cancers (Basel). 2021;13. https:\/\/doi.org\/10.3390\/cancers13112745","DOI":"10.3390\/cancers13112745"},{"key":"6643_CR183","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13048-024-01497-y","volume":"17","author":"X Tang","year":"2024","unstructured":"Tang X, Ma C, Wu Q, Yu M. Ovarian cancer derived extracellular vesicles promote the cancer progression and angiogenesis by mediating M2 macrophages polarization. J Ovarian Res. 2024;17:172. https:\/\/doi.org\/10.1186\/s13048-024-01497-y","journal-title":"J Ovarian Res"},{"key":"6643_CR184","doi-asserted-by":"publisher","first-page":"1042730","DOI":"10.3389\/fonc.2022.1042730","volume":"12","author":"D Schweer","year":"2022","unstructured":"Schweer D, Anand N, Anderson A, McCorkle JR, Neupane K, Nail AN, Harvey B, Hill KS, Ueland F, Richards C, Kolesar J. Human macrophage-engineered vesicles for utilization in ovarian cancer treatment. Front Oncol. 2022;12:1042730. https:\/\/doi.org\/10.3389\/fonc.2022.1042730","journal-title":"Front Oncol"},{"key":"6643_CR185","doi-asserted-by":"publisher","first-page":"a008748","DOI":"10.1101\/cshperspect.a008748","volume":"5","author":"A Hochreiter-Hufford","year":"2013","unstructured":"Hochreiter-Hufford A, Ravichandran KS. Clearing the dead: apoptotic cell sensing, recognition, engulfment, and digestion. Cold Spring Harb Perspect Biol. 2013;5:a008748. https:\/\/doi.org\/10.1101\/cshperspect.a008748","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"6643_CR186","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3390\/vaccines3030703","volume":"3","author":"JC Mbongue","year":"2015","unstructured":"Mbongue JC, Nicholas DA, Torrez TW, Kim NS, Firek AF, Langridge WH. The role of indoleamine 2, 3-Dioxygenase in immune suppression and autoimmunity. Vaccines (Basel). 2015;3:703\u201329. https:\/\/doi.org\/10.3390\/vaccines3030703","journal-title":"Vaccines (Basel)"},{"key":"6643_CR187","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/nm934","volume":"9","author":"C Uyttenhove","year":"2003","unstructured":"Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ. Evidence for a tumoral immune resistance mechanism based on Tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003;9:1269\u201374. https:\/\/doi.org\/10.1038\/nm934","journal-title":"Nat Med"},{"key":"6643_CR188","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3389\/fonc.2018.00423","volume":"8","author":"T Komiya","year":"2018","unstructured":"Komiya T, Huang CH. Updates in the clinical development of Epacadostat and other indoleamine 2,3-Dioxygenase 1 inhibitors (IDO1) for human cancers. Front Oncol. 2018;8:423. https:\/\/doi.org\/10.3389\/fonc.2018.00423","journal-title":"Front Oncol"},{"key":"6643_CR189","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1200\/JCO.2018.78.9602","volume":"36","author":"TC Mitchell","year":"2018","unstructured":"Mitchell TC, Hamid O, Smith DC, Bauer TM, Wasser JS, Olszanski AJ, Luke JJ, Balmanoukian AS, Schmidt EV, Zhao Y, et al. Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, Open-Label phase I\/II trial (ECHO-202\/KEYNOTE-037). J Clin Oncol. 2018;36:3223\u201330. https:\/\/doi.org\/10.1200\/JCO.2018.78.9602","journal-title":"J Clin Oncol"},{"key":"6643_CR190","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s40425-018-0351-9","volume":"6","author":"A Nayak-Kapoor","year":"2018","unstructured":"Nayak-Kapoor A, Hao Z, Sadek R, Dobbins R, Marshall L, Vahanian NN, Ramsey J, Kennedy W, Mautino E, Link MR, C.J., et al. Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors. J Immunother Cancer. 2018;6:61. https:\/\/doi.org\/10.1186\/s40425-018-0351-9","journal-title":"J Immunother Cancer"},{"key":"6643_CR191","doi-asserted-by":"publisher","first-page":"eabg8402","DOI":"10.1126\/scitranslmed.abg8402","volume":"14","author":"K Odunsi","year":"2022","unstructured":"Odunsi K, Qian F, Lugade AA, Yu H, Geller MA, Fling SP, Kaiser JC, Lacroix AM, D\u2019Amico L, Ramchurren N, et al. Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses. Sci Transl Med. 2022;14:eabg8402. https:\/\/doi.org\/10.1126\/scitranslmed.abg8402","journal-title":"Sci Transl Med"},{"key":"6643_CR192","doi-asserted-by":"publisher","unstructured":"Zou Z, Lin H, Li M, Lin B. Tumor\u2013\u2009associated macrophage polarization in the inflammatory tumor microenvironment. Frontiers in Oncology. 2023;13. https:\/\/doi.org\/10.3389\/fonc.2023.1103149","DOI":"10.3389\/fonc.2023.1103149"},{"key":"6643_CR193","doi-asserted-by":"publisher","first-page":"6171","DOI":"10.1158\/0008-5472.CAN-10-0153","volume":"70","author":"RK Shrimali","year":"2010","unstructured":"Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 2010;70:6171\u201380. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-0153","journal-title":"Cancer Res"},{"key":"6643_CR194","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1001\/jamaoncol.2019.3343","volume":"5","author":"JF Liu","year":"2019","unstructured":"Liu JF, Herold C, Gray KP, Penson RT, Horowitz N, Konstantinopoulos PA, Castro CM, Hill SJ, Curtis J, Luo W, et al. Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer: A phase 2 clinical trial. JAMA Oncol. 2019;5:1731\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2019.3343","journal-title":"JAMA Oncol"},{"key":"6643_CR195","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1186\/s40064-016-2660-0","volume":"5","author":"GH Giornelli","year":"2016","unstructured":"Giornelli GH. Management of relapsed ovarian cancer: a review. Springerplus. 2016;5:1197. https:\/\/doi.org\/10.1186\/s40064-016-2660-0","journal-title":"Springerplus"},{"key":"6643_CR196","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/emmm.201202367","volume":"5","author":"K Izumi","year":"2013","unstructured":"Izumi K, Fang LY, Mizokami A, Namiki M, Li L, Lin WJ, Chang C. Targeting the androgen receptor with SiRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2\/CCR2-induced STAT3 activation. EMBO Mol Med. 2013;5:1383\u2013401. https:\/\/doi.org\/10.1002\/emmm.201202367","journal-title":"EMBO Mol Med"},{"key":"6643_CR197","doi-asserted-by":"publisher","first-page":"947","DOI":"10.2174\/1389450122999210128180058","volume":"22","author":"V Sethuraman","year":"2021","unstructured":"Sethuraman V, Janakiraman K, Krishnaswami V, Kandasamy R. Recent progress in Stimuli-Responsive intelligent nano scale drug delivery systems: A special focus towards pH-Sensitive systems. Curr Drug Targets. 2021;22:947\u201366. https:\/\/doi.org\/10.2174\/1389450122999210128180058","journal-title":"Curr Drug Targets"},{"key":"6643_CR198","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1039\/c9nr08558k","volume":"12","author":"Y Li","year":"2020","unstructured":"Li Y, Niu Y, Zhu J, Gao C, Xu Q, He Z, Chen D, Xu M, Liu Y. Tailor-made legumain\/ph dual-responsive doxorubicin prodrug-embedded nanoparticles for efficient anticancer drug delivery and in situ monitoring of drug release. Nanoscale. 2020;12:2673\u201385. https:\/\/doi.org\/10.1039\/c9nr08558k","journal-title":"Nanoscale"},{"key":"6643_CR199","doi-asserted-by":"publisher","first-page":"7378","DOI":"10.1039\/d3nr06333j","volume":"16","author":"MM Khan","year":"2024","unstructured":"Khan MM, Li Y, Zhou Z, Ni A, Saiding Q, Qin D, Tao W, Chen W. Macrophage-modulating nanomedicine for cancer immunotherapy. Nanoscale. 2024;16:7378\u201386. https:\/\/doi.org\/10.1039\/d3nr06333j","journal-title":"Nanoscale"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06643-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06643-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06643-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T05:00:17Z","timestamp":1748926817000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06643-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":199,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6643"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06643-8","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]},"assertion":[{"value":"19 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests\u201d in this section.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"623"}}